A small study from Japan suggests pembrolizumab and chemotherapy alone may sustain strong survival outcomes in select PD-L1–high NSCLC patients
Radiation-Free Immunotherapy Approach Offers…
A small study from Japan suggests pembrolizumab and chemotherapy alone may sustain strong survival outcomes in select PD-L1–high NSCLC patients